Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharming Group (PHGUF)
OTHER OTC:PHGUF
Pharming Group (PHGUF) Stock Price & Analysis
87 Followers
PHGUF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.76 - $1.43
Previous Close$0.84
Volume700.00
Average Volume (3M)1.22K
Market Cap
$566.80M
Enterprise Value$524.92M
Total Cash (Recent Filing)$213.42M
Total Debt (Recent Filing)$171.54M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 01, 2024Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding671,073,243
10 Day Avg. Volume100
30 Day Avg. Volume1,220
Standard Deviation0.16
R-Squared0.15
Alpha-0.00056
Financial Highlights & Ratios
Price to Book (P/B)5.36
Price to Sales (P/S)2.54
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.03
Enterprise Value/Gross Profit2.38
Enterprise Value/Ebitda14.80
Forecast
1Y Price Target
$1.79Price Target Upside111.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Pharming Group News
PremiumCompany Announcements
Pharming Group Announces Upcoming Financial Results
Bulls Say, Bears Say
Bulls Say
Product DemandDemand remains robust, with almost 70 new patient enrollments in 1Q24.
Revenue GrowthRuconest revenues increased 8.2% to $46.0m, in line with estimates.
Sales PerformanceJoenja sales increased 24% vs 4Q23 to $9.6m, confirming the encouraging launch trajectory.
Bears Say
EarningsOperating loss of $16.3m was greater than the $12.4m loss estimate.
Regulatory ChallengesThe reluctance of EMA to approve Joenja on a relatively minor issue with the regulatory starting materials used in the drug manufacturing process is baffling.
Regulatory DelaysFrustrating and surprising outcome to a long regulatory journey, with delays caused by the EMA's request for further OLE data and the decision to convene an Ad Hoc Expert Group.
---
Ownership Overview
0.00%
Insiders
2.48% Mutual Funds
2.51% Other Institutional Investors
95.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PHGUF FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was $0.76 and its highest was $1.43 in the past 12 months.
What is Pharming Group’s market cap?
Currently, no data Available
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Aug 01, 2024 which is in 3 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on May 08, 2024. The company reported -$0.019 earnings per share for the quarter, missing the consensus estimate of $0.001 by -$0.02.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Undervalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is $0.
How many shares outstanding does Pharming Group have?
Pharming Group has 678,354,300 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of -$0.019 in its last earnings report, missing expectations of $0.001. Following the earnings report the stock price went down -2.083%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in PHGUF
---
Pharming Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.70%
12-Months-Change
Fundamentals
Return on Equity
-5.11%
Trailing 12-Months
Asset Growth
4.41%
Trailing 12-Months
Company Description
Pharming Group
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
---
PHGUF Company Deck
---
PHGUF Earnings Call
Q1 2024
0:00 / 0:00
---
PHGUF Stock 12 Month Forecast
Average Price Target
$1.79
▲(111.16% Upside)
Technical Analysis
Best Analysts Covering PHGUF
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-25.88%
reiterated a buy rating 3 months ago
Copying Alistair Campbell's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -25.88% per trade.
---